The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction

The Impact of Functional Medicine On Wound Healing From Delayed Autologous Breast Reconstruction - A Feasibility Study

This study will examine if a functional medicine approach, delivered as an adjunct to standard of care, is feasible, safe, clinically beneficial and cost-effective for patients undergoing autologous breast reconstruction.

Study Overview

• Status: Active, not recruiting
• Conditions: Breast Reconstruction
• Intervention / Treatment: Procedure: Delayed autologous breast reconstruction; Behavioral: Perioperative Functional Medicine (FM) Care

Detailed Description

Autologous microsurgical breast reconstruction is associated with a protracted recovery and a significant amount of opioid utilization. Many institutions have "Enhanced Recovery After Surgery (ERAS)" protocols that utilize multi-modality therapy to decrease opioid use, length of stay, hospital costs and expedite recovery. However, nutrition-based interventions used perioperatively are not currently part of ERAS protocols for surgical sub-specialties, including breast surgery despite ample literature that nutrition (with or without supplements) can improve surgical wound healing and other outcomes.

The functional medicine model of care expands upon the conventional medicine model of care by providing a unique operating system that works to reverse illness, promote health and optimize function. A foundation of functional medicine is the use of food as medicine to prevent, treat and reverse chronic disease. Dietary supplements are used as an adjunct to nutrition-based interventions. Dietitians support patients with implementing food plans, and health coaches support patients through lifestyle and behavioral changes focused on sleep, exercise and movement and stress reduction.

This study will examine the feasibility of implementing a functional medicine-based intervention focused on nutrition and lifestyle, and the ability of the intervention to improve wound healing and decrease various post-operative complications in patients undergoing autologous breast reconstruction.

All participants will be asked to attend study visits, complete questionnaires and have their blood drawn. Participants randomized to standard of care plus functional medicine will be asked to also follow a specific food plan, take specific dietary supplements, exercise and engage in stress reduction techniques for 3 months prior to and after surgery. The study duration is 6 months.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Ohio
    • Cleveland, Ohio, United States, 44195
      • Cleveland Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Undergoing uni- or bilateral delayed abdominally-based breast reconstruction at the Cleveland Clinic.
• Women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, implantable or injectable contraceptives or surgical sterilization) for the duration of the study.
• Capable of providing written informed consent prior to any protocol-specified procedures.
• Willing to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

• BMI > 37
• Women who are pregnant, nursing, or planning pregnancy during the trial.
• Have a serious concomitant illness that could interfere with the subject's participation in the trial (allergy preventing supplement usage)
• Undergoing chemotherapy during proposed nutritional intervention (3 months before or after surgery).
• Are unable to or unwilling to undergo multiple venipunctures because of poor tolerability or lack of easy access.
• Clinical diagnosis of cognitive impairment or dementia.
• Known sensitivity to nutritional supplements.
• History of being seen or had intervention/care in Functional Medicine or following Functional Medicine principles.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control (Standard of Care (SOC)); Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay.	Procedure: Delayed autologous breast reconstruction; SOC: Delayed autologous breast reconstruction
Experimental: SOC + Functional Medicine; Reconstructive surgical technique, delayed autologous breast reconstruction, and usual local anesthesia and analgesia during hospital stay. Perioperative nutrition and lifestyle-based interventions along with select dietary supplements.	Procedure: Delayed autologous breast reconstruction; SOC: Delayed autologous breast reconstruction; Behavioral: Perioperative Functional Medicine (FM) Care; SOC plus FM: A food plan that encourages consumption of nutrient-dense whole foods. It provides adequate protein, balanced quality fats and foods which contain targeted nutrients essential to proper wound healing. Select dietary supplements will be provided as an adjunct to the food plan. Health coaching will support optimal sleep, adequate movement/exercise and stress reduction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Feasibility defined by percent randomized.	Success will be defined as enrolling and randomizing 25% or more of those screened per arm.	Baseline
Number of in-person visits completed.	Number of in-person visits completed.	Up to 26 weeks
Number of virtual visits completed.	Number of virtual visits completed.	Up to 26 weeks
Adherence to recommended dietary intervention.	Percent of participants adhering to recommended dietary intervention.	Up to 26 weeks
Adherence to recommended lifestyle interventions.	Percent of participants adhering to lifestyle interventions.	Up to 26 weeks
Adherence to prescribed dietary supplementation.	Percent of participants adhering to prescribed dietary supplementation.	Up to 26 weeks
Number of Serious Adverse Events (SAE's).	Number of Serious Adverse Events (SAE's).	Up to 26 weeks
Percent completion of study-specific surveys.	Percent of the following surveys completed: BreastQ (baseline, wks 12, and 26); PROMIS Questionnaire (baseline and wks 5, 12 and 26); Medical Symptom Questionnaire (MSQ) (baseline and wks 5, 12 and 26); Nutrition and Lifestyle Adherence Survey (randomization and then weekly for the duration of the study); Dietary Supplementation Adherence Survey (only those randomized to SOC plus functional medicine; wk1 and then weekly for the duration of the study) Note: the BRA and SKIN surveys are not completed by the patient, but by the provider.	Up to 26 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of re-operations for wound management.	Number of re-operations for wound management (mean & standard deviation).	Up to 26 weeks
Number of hospital re-admissions.	Number of hospital re-admissions (mean & standard deviation).	Up to 26 weeks
Length-of-stay upon hospital re-admission.	Length-of-stay upon hospital re-admission (mean & standard deviation).	Up to 26 weeks
Number of antibiotic prescriptions.	Infection rates assessed by number of antibiotic prescriptions (mean & standard deviation). Standard of care (SOC), post-surgery prophylactic antibiotic prescriptions will not be considered.	Up to 26 weeks
Correlate all post-operative complications with the predicted risk from the BRA scoring system.	Surgical complications will be measured within each arm and the predicted risk will be compared to the actual incidence. Surgical complications is defined as the total number of all the complications (eg. surgical site infection, seroma, dehiscence, flap loss and reoperation). The minimum and maximum probabilities of experiencing surgical complications based on the BRA scoring system are 11.7% and 57.9%, respectively. The American Society of Plastic Surgeons Tracking Operations and Outcomes for Plastic Surgeons (TOPS) database which tracks 30-day outcomes for plastic surgery was used to determine the minimum and maximum probabilities of this complication.	Up to 26 weeks
Correlate post-operative surgical site infection complications with the predicted risk from the BRA scoring system.	Surgical site infection (SSI) will be measured within each arm and the predicted risk will be compared to the actual incidence. SSI is defined as a superficial SSI or deep incisional SSI. The minimum and maximum probabilities of experiencing a SSI based on the BRA scoring system are 2.7% and 54.8%, respectively. The American College of Surgeons National Surgical Quality Improvement Program (NSQIP) database which tracks 30-day outcomes for plastic surgery was used to determine the minimum and maximum probabilities of this complication.	Up to 26 weeks
Correlate post-operative seroma complications with the predicted risk from the BRA scoring system.	Seroma will be measured within each arm and the predicted risk will be compared to the actual incidence. Seroma is defined as a fluid collection that develops after surgery necessitating aspiration or surgical intervention. The minimum and maximum probabilities of experiencing a seroma based on the BRA scoring system are 1.8% and 13.8%, respectively. The American Society of Plastic Surgeons Tracking Operations and Outcomes for Plastic Surgeons (TOPS) database which tracks 30-day outcomes for plastic surgery was used to determine the minimum and maximum probabilities of this complication.	Up to 26 weeks
Correlate post-operative dehiscence complications with the predicted risk from the BRA scoring system.	Dehiscence will be measured within each arm and the predicted risk will be compared to the actual incidence. Dehiscence is defined as separation of the layers of a surgical wound, which may be partial or complete with disruption of the fascia. The minimum and maximum probabilities of experiencing dehiscence based on the BRA scoring system are 3.7% and 50.2%, respectively. The American Society of Plastic Surgeons Tracking Operations and Outcomes for Plastic Surgeons (TOPS) database which tracks 30-day outcomes for plastic surgery was used to determine the minimum and maximum probabilities of this complication.	Up to 26 weeks
Correlate post-operative flap loss complications with the predicted risk from the BRA scoring system.	Flap loss will be measured within each arm and the predicted risk will be compared to the actual incidence. Flap loss is defined as complete removal of flap after complication. The minimum and maximum probabilities of experiencing flap loss based on the BRA scoring system are 4.3% and 49.6%, respectively. The American Society of Plastic Surgeons Tracking Operations and Outcomes for Plastic Surgeons (TOPS) database which tracks 30-day outcomes for plastic surgery was used to determine the minimum and maximum probabilities of this complication.	Up to 26 weeks
Correlate post-operative reoperation complications with the predicted risk from the BRA scoring system.	Reoperation will be measured within each arm and the predicted risk will be compared to the actual incidence. Reoperation is defined as a return to operating room for a procedure. This does not refer to procedures performed in the office under local. The minimum and maximum probabilities of experiencing reoperation based on the BRA scoring system are 4.3% and 23.0%, respectively. The American Society of Plastic Surgeons Tracking Operations and Outcomes for Plastic Surgeons (TOPS) database which tracks 30-day outcomes for plastic surgery was used to determine the minimum and maximum probabilities of this complication.	Up to 26 weeks
Evaluate narcotic utilization while in the hospital.	Morphine utilization (Oral morphine equivalents (mg)).	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (Oral morphine equivalents (mg/kg)).	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (Oral morphine equivalents (mg/kg/day)).	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (IV morphine equivalents (mg)).	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (IV morphine equivalents (mg/kg)).	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (IV morphine equivalents (mg/kg/day).	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (total morphine equivalents (mg) while in hospital.	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (total morphine equivalents (mg/kg) while in hospital.	While in hospital, an average of 3 days
Evaluate narcotic utilization while in the hospital.	Morphine utilization (total morphine equivalents (mg/kg/day) while in hospital.	While in hospital, an average of 3 days
Change in Complete Blood Count with Differential (CBC).	Change in CBC (mean & standard deviation).	Baseline to 12 weeks
Change in Complete Blood Count with Differential (CBC).	Change in CBC (mean & standard deviation).	Baseline to 26 weeks
Change in Comprehensive Metabolic Pane (CMP).	Change in CMP (mean & standard deviation).	Baseline to 12 weeks
Change in Comprehensive Metabolic Pane (CMP).	Change in CMP (mean & standard deviation).	Baseline to 26 weeks
Change in Hemoglobin A1c (HbA1c).	Change in % HbA1c (mean & standard deviation).	Baseline to 12 weeks
Change in Hemoglobin A1c (HbA1c).	Change in % HbA1c (mean & standard deviation).	Baseline to 26 weeks
Change in nuclear magnetic resonance (NMR) LipoProfile.	Change in NMR LipoProfile (mean & standard deviation). LDL Particle Number (L): (Normal Range: < 1000 nmol) LDL Cholesterol (dL): (Normal Range: 0 - 99 mg) HDL Cholesterol (dL) : (Normal Range: >39 mg) Triglycerides (dL): (Normal Range: 0 - 149 mg) Total Cholesterol (dL): (Normal Range: 100 - 199 mg) Total HDL Particles (L): (Normal Range: >=30.5 umol) Small LDL-P (L): (Normal Range: < =527 nmol) Large VLDL-P (L): (Normal Range: < =2.7 nmol/L) Large HDL-P (L): (Normal Range: >=4.8 umol) VLDL Size (nm): (Normal Range: < =46.6 nm) LDL Size (nm): (Normal Range: >20.5 nm) HDL Size (nm): (Normal Range: >=9.2 nm) LP/IR Score: (Normal Range: < =45)	Baseline to 12 weeks
Change in NMR LipoProfile.	Change in NMR LipoProfile (mean & standard deviation). LDL Particle Number (L): (Normal Range: < 1000 nmol) LDL Cholesterol (dL): (Normal Range: 0 - 99 mg) HDL Cholesterol (dL) : (Normal Range: >39 mg) Triglycerides (dL): (Normal Range: 0 - 149 mg) Total Cholesterol (dL): (Normal Range: 100 - 199 mg) Total HDL Particles (L): (Normal Range: >=30.5 umol) Small LDL-P (L): (Normal Range: < =527 nmol) Large VLDL-P (L): (Normal Range: < =2.7 nmol/L) Large HDL-P (L): (Normal Range: >=4.8 umol) VLDL Size (nm): (Normal Range: < =46.6 nm) LDL Size (nm): (Normal Range: >20.5 nm) HDL Size (nm): (Normal Range: >=9.2 nm) LP/IR Score: (Normal Range: < =45)	Baseline to 26 weeks
Change in high-sensitivity C-Reactive Protein (hsCRP).	Change in hsCRP (mean & standard deviation).	Baseline to 12 weeks
Change in high-sensitivity C-Reactive Protein (hsCRP).	Change in hsCRP (mean & standard deviation).	Baseline to 26 weeks
Change in Vitamin D.	Change in Vitamin D (ng/mL) (mean & standard deviation).	Baseline to 12 weeks
Change in Vitamin D.	Change in Vitamin D (ng/mL) (mean & standard deviation).	Baseline to 26 weeks
Change in OmegaCheck.	Change in OmegaCheck (mean & standard deviation). Arachidonic Acid (% by wt) Arachidonic Acid/EPA ratio Docosahexaenoic acid (DHA) (% by wt) Docosapentaenoic acid (DPA) (% by wt) Eicosapentaenoic acid (EPA) (% by wt) Linoleic Acid (% by wt) Omega-3 total (% by wt) Omega-6 total (% by wt) Omega-6/3 Ratio OmegaCheck (total EPA+DPA+DHA reported as % by wt)	Baseline to 12 weeks
Change in OmegaCheck.	Change in OmegaCheck (mean & standard deviation). Arachidonic Acid (% by wt) Arachidonic Acid/EPA ratio Docosahexaenoic acid (DHA) (% by wt) Docosapentaenoic acid (DPA) (% by wt) Eicosapentaenoic acid (EPA) (% by wt) Linoleic Acid (% by wt) Omega-3 total (% by wt) Omega-6 total (% by wt) Omega-6/3 Ratio OmegaCheck (total EPA+DPA+DHA reported as % by wt)	Baseline to 26 weeks
Total healthcare costs.	Measure cost of laboratory testing, dietary supplementation, initial hospital length of stay, and post-surgical complications requiring intervention (if applicable).	At 26 weeks
Net change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Physical Health (GPH) scores.	Change in PROMIS GPH scores (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes	Baseline to week 12
Net change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Physical Health (GPH) scores.	Change in PROMIS GPH scores (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes	Baseline to week 26
Net change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Physical Health (GPH) scores.	Change in PROMIS GPH scores (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes.	Baseline to week 5
Clinically-meaningful change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Physical Health (GPH) scores.	Clinically-meaningful change in PROMIS GPH, or improvements in 5.00 points or more (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes. Improvement: ≥5.00 points Slightly Better: 2.50 to 4.99 points Similar: -2.49 to 2.49 points Slightly Worse: -2.50 to -4.99 points	Baseline to week 5
Clinically-meaningful change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Physical Health (GPH) scores.	Clinically-meaningful change in PROMIS GPH, or improvements in 5.00 points or more (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes. Improvement: ≥5.00 points Slightly Better: 2.50 to 4.99 points Similar: -2.49 to 2.49 points Slightly Worse: -2.50 to -4.99 points	Baseline to week 12
Clinically-meaningful change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Physical Health (GPH) scores.	Clinically-meaningful change in PROMIS GPH, or improvements in 5.00 points or more (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes. Improvement: ≥5.00 points Slightly Better: 2.50 to 4.99 points Similar: -2.49 to 2.49 points Slightly Worse: -2.50 to -4.99 points	Baseline to week 26
Change in mean value of the continuous variable of PROMIS GPH.	Change in mean value of the continuous variable of PROMIS GPH.	Baseline to week 5
Change in mean value of the continuous variable of PROMIS GPH.	Change in mean value of the continuous variable of PROMIS GPH.	Baseline to week 12
Change in mean value of the continuous variable of PROMIS GPH.	Change in mean value of the continuous variable of PROMIS GPH.	Baseline to week 26
Net change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Mental Health (GMH).	Change in PROMIS GMH scores (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes.	Baseline to week 5
Net change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Mental Health (GMH).	Change in PROMIS GMH scores (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes.	Baseline to week 12
Net change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Mental Health (GMH).	Change in PROMIS GMH scores (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes.	Baseline to week 26
Clinically-meaningful change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Mental Health (GMH) scores.	Clinically-meaningful change in PROMIS GMH, or improvements in 5.00 points or more (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes. Improvement: ≥5.00 points Slightly Better: 2.50 to 4.99 points Similar: -2.49 to 2.49 points Slightly Worse: -2.50 to -4.99 points	Baseline to week 5
Clinically-meaningful change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Mental Health (GMH) scores.	Clinically-meaningful change in PROMIS GMH, or improvements in 5.00 points or more (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes. Improvement: ≥5.00 points Slightly Better: 2.50 to 4.99 points Similar: -2.49 to 2.49 points Slightly Worse: -2.50 to -4.99 points	Baseline to week 12
Clinically-meaningful change in Patient-Reported Outcome Measurement Information System (PROMIS) Global Mental Health (GMH) scores.	Clinically-meaningful change in PROMIS GMH, or improvements in 5.00 points or more (mean & standard deviation). PROMIS is an NIH-validated set of person-centered measures that evaluates and monitors physical, mental, and social health in adults and children within the general population and in those living with chronic conditions. This is considered SOC for the Center for Functional Medicine. Scores are transformed into T-Scores. The mean (SD) of the US General Population is 50 (10). Higher scores mean better outcomes. Improvement: ≥5.00 points Slightly Better: 2.50 to 4.99 points Similar: -2.49 to 2.49 points Slightly Worse: -2.50 to -4.99 points	Baseline to week 26
Change in mean value of the continuous variable of PROMIS GMH.	Change in mean value of the continuous variable of PROMIS GMH.	Baseline to week 5
Change in mean value of the continuous variable of PROMIS GMH.	Change in mean value of the continuous variable of PROMIS GMH.	Baseline to week 12
Change in mean value of the continuous variable of PROMIS GMH.	Change in mean value of the continuous variable of PROMIS GMH.	Baseline to week 26
Change in Breast-Q scores.	Change in Breast-Q score (mean & standard deviation). Breast-Q is a validated comprehensive evaluation of breast health and wellness. Transformed scores range from 0-100 with higher score means greater satisfaction or better QoL.	Baseline to week 12
Change in Breast-Q scores.	Change in Breast-Q score (mean & standard deviation). Breast-Q is a validated comprehensive evaluation of breast health and wellness. Transformed scores range from 0-100 with higher score means greater satisfaction or better QoL.	Baseline to week 26
Change in Medical System Questionnaire (MSQ) scores.	Change participant's global symptoms measured by change in MSQ scores (mean & standard deviation). The MSQ identifies symptoms that a patient has experienced over the previous 48 hours based upon their health profile. The MSQ utilizes a semantic differential scale to determine how often a patient is experiencing a specific symptom and to track a participant's progress. All scores are totaled and higher MSQ scores indicate worsening of symptoms while lower scores indicate symptom improvement. This is considered SOC for the Center for Functional Medicine. Total Score Range: 0-352, with higher scores meaning worse outcomes.	Baseline to week 5
Change in Medical System Questionnaire (MSQ) scores.	Change participant's global symptoms measured by change in MSQ scores (mean & standard deviation). The MSQ identifies symptoms that a patient has experienced over the previous 48 hours based upon their health profile. The MSQ utilizes a semantic differential scale to determine how often a patient is experiencing a specific symptom and to track a participant's progress. All scores are totaled and higher MSQ scores indicate worsening of symptoms while lower scores indicate symptom improvement. This is considered SOC for the Center for Functional Medicine. Total Score Range: 0-352, with higher scores meaning worse outcomes.	Baseline to week 12
Change in Medical System Questionnaire (MSQ) scores.	Change participant's global symptoms measured by change in MSQ scores (mean & standard deviation). The MSQ identifies symptoms that a patient has experienced over the previous 48 hours based upon their health profile. The MSQ utilizes a semantic differential scale to determine how often a patient is experiencing a specific symptom and to track a participant's progress. All scores are totaled and higher MSQ scores indicate worsening of symptoms while lower scores indicate symptom improvement. This is considered SOC for the Center for Functional Medicine. Total Score Range: 0-352, with higher scores meaning worse outcomes.	Baseline to week 26
Change in Nutrition and Lifestyle Adherence Survey scores.	Nutrition and lifestyle changes as measured by changes in Nutrition and Lifestyle Adherence Survey scores, which assesses participant diet, exercise and stress management in the prior week. Nutrition: Range of available points: 0-45 (higher = better) Sleep: Range of available points: 0-3 points (higher = better) Exercise/Movement: Range of available points: 0-20 points (higher = better) Stress Management: 0-8 points (higher = better) Total Composite Score Range: 0-76 (higher = better)	Baseline to week 12
Change in Nutrition and Lifestyle Adherence Survey scores.	Nutrition and lifestyle changes as measured by changes in Nutrition and Lifestyle Adherence Survey scores, which assesses participant diet, exercise and stress management in the prior week. Nutrition: Range of available points: 0-45 (higher = better) Sleep: Range of available points: 0-3 points (higher = better) Exercise/Movement: Range of available points: 0-20 points (higher = better) Stress Management: 0-8 points (higher = better) Total Composite Score Range: 0-76 (higher = better)	Baseline to week 26
Change in Dietary Supplement Adherence Survey scores.	Dietary supplementation use as part of the study measured by change Dietary Supplement Adherence Survey scores. O.N.E Omega: 0-4 points Probiotic 50B: 0-4 points Vitamin D3: 0-4 points Whey Basics: 0-4 points Curcumin with Bioperine: 0-4 points Zinc 30: 0-4 points Bromelain: 0-4 points; Only taken 1 week prior to and after surgery Total Score Range: 0-24 (except for the 1 week prior to and after surgery when the total score range is: 0-28, higher = better)	Baseline to week 12
Change in Dietary Supplement Adherence Survey scores	Dietary supplementation use as part of the study measured by change Dietary Supplement Adherence Survey scores. O.N.E Omega: 0-4 points Probiotic 50B: 0-4 points Vitamin D3: 0-4 points Whey Basics: 0-4 points Curcumin with Bioperine: 0-4 points Zinc 30: 0-4 points Bromelain: 0-4 points; Only taken 1 week prior to and after surgery Total Score Range: 0-24 (except for the 1 week prior to and after surgery when the total score range is: 0-28 higher = better)	Baseline to week 26
Number of days wounds necessitate dressing changes or packing post-surgery.	Evaluation of wound healing by by assessing the number of days wounds necessitate dressing changes or packing post-surgery (mean & standard deviation).	At 26 weeks
SKIN Survey composite scores.	The SKIN Survey composite score assesses severity and extent of mastectomy skin flap necrosis (MSFN) (eg. A1, B3, D2, etc.). Depth of MSFN is assessed from A to D: A = None, no evidence of MSFN B = Color change of skin flap suggesting impaired perfusion or ischemic injury (may be cyanosis or erythema) C = Partial thickness skin flap necrosis resulting in at least epidermal sloughing D = Full thickness skin flap necrosis Surface area of MSFN (%) is assessed by providing a value from 1 to 4: - None 0%; - Breast, change affects 1-10% of breast skin or NAC, change affects 1-10% of nipple-areolar complex; - Breast, change affects 11-30 % of breast skin or NAC, 11-30% of NAC affected, or total nipple involvement; - Change affects >30% of breast skin or 30% of NAC	At 14 weeks
SKIN Survey composite scores.	The SKIN Survey composite score assesses severity and extent of mastectomy skin flap necrosis (MSFN) (eg. A1, B3, D2, etc.). Depth of MSFN is assessed from A to D: A = None, no evidence of MSFN B = Color change of skin flap suggesting impaired perfusion or ischemic injury (may be cyanosis or erythema) C = Partial thickness skin flap necrosis resulting in at least epidermal sloughing D = Full thickness skin flap necrosis Surface area of MSFN (%) is assessed by providing a value from 1 to 4: - None 0%; - Breast, change affects 1-10% of breast skin or NAC, change affects 1-10% of nipple-areolar complex; - Breast, change affects 11-30 % of breast skin or NAC, 11-30% of NAC affected, or total nipple involvement; - Change affects >30% of breast skin or 30% of NAC	At 15 weeks
SKIN Survey composite scores.	The SKIN Survey composite score assesses severity and extent of mastectomy skin flap necrosis (MSFN) (eg. A1, B3, D2, etc.). Depth of MSFN is assessed from A to D: A = None, no evidence of MSFN B = Color change of skin flap suggesting impaired perfusion or ischemic injury (may be cyanosis or erythema) C = Partial thickness skin flap necrosis resulting in at least epidermal sloughing D = Full thickness skin flap necrosis Surface area of MSFN (%) is assessed by providing a value from 1 to 4: - None 0%; - Breast, change affects 1-10% of breast skin or NAC, change affects 1-10% of nipple-areolar complex; - Breast, change affects 11-30 % of breast skin or NAC, 11-30% of NAC affected, or total nipple involvement; - Change affects >30% of breast skin or 30% of NAC	At 17 weeks
Average incision length.	Wound healing as measured by average incision length (mean & standard deviation).	At 14 weeks
Average incision length.	Wound healing as measured by average incision length (mean & standard deviation).	At 15 weeks
Average incision length.	Wound healing as measured by average incision length (mean & standard deviation).	At 17 weeks
Average dehiscence length.	Wound healing as measured by average dehiscence length (separation of the incision line) (mean & standard deviation).	At 14 weeks
Average dehiscence length.	Wound healing as measured by average dehiscence (separation of the incision line) length (mean & standard deviation).	At 15 weeks
Average dehiscence length.	Wound healing as measured by average dehiscence (separation of the incision line) length (mean & standard deviation).	At 17 weeks

Collaborators and Investigators

• Sponsor: Case Comprehensive Cancer Center
• Investigators: Principal Investigator: Amanda Shallcross, ND, MPH, The Cleveland Clinic

Study record dates

Study Major Dates

• Study Start (Actual): February 20, 2023
• Primary Completion (Estimated): October 1, 2024
• Study Completion (Estimated): May 1, 2025

Study Registration Dates

• First Submitted: June 28, 2021
• First Submitted That Met QC Criteria: August 24, 2021
• First Posted (Actual): August 31, 2021

Study Record Updates

• Last Update Posted (Actual): May 7, 2024
• Last Update Submitted That Met QC Criteria: May 6, 2024
• Last Verified: May 1, 2024

More Information

Terms related to this study

• Other Study ID Numbers: CASE4119

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plans to share Individual Participant Data (IPD)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No